A recent study (P Tandon et al. Inflamm Bowel Dis 2017; 23: 551-60) was a systemic review regarding the accuracy of blood-based testing for predicting colonic CMV reactivation in patients with inflammatory bowel disease. The review identified 9 studies. The overall sensitivity of blood-based testing (either pp65 antigenemia or blood PCR) for CMV was 50.8% and the specificity was 99.9%. Blood PCR was better at 60% sensitivity.
My take: Blood-based tests are not sensitive enough to exclude colonic CMV reactivation. The authors recommend the use of immunohistochemistry or tissue PCR for detecting CMV reactivation in inflammatory bowel disease.
Related blog posts:
- IBD Updates -January 2017
- Utility of Antiviral Therapy for Cytomegalovirus in the … – gutsandgrowth
- Will infliximab worsen flareups associated with CMV?